

**Global survey on
National Vaccine Deployment and
Vaccination Plans
for pandemic A(H1N1) 2009 vaccine – 2010**

Report of Findings

World Health Organization

May 2013

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Contents

Abbreviations and acronyms	5
Acknowledgements.....	6
INTRODUCTION.....	9
Aim of the study.....	9
MATERIALS AND METHODS	9
Study design.....	9
Data collection	9
Other data sources.....	10
Data analysis	10
RESULTS	11
I. Management and organization: oversight, supervision, and funding.....	12
Importation Barriers	12
Vaccine distribution, delivery, and tracking.....	13
Surge capacity for vaccine deployment and vaccination.....	14
II. Vaccination strategies.....	15
Access to vaccine and sources	15
III. Vaccine utilization and coverage	16
African Region	17
Americas Region.....	19
Eastern Mediterranean Region.....	20
European Region.....	21
South-East Asia Region	23
Western Pacific Region	24
IV. Supply chain logistics	26
Capacity for Supply chain and logistics.....	26
Delivery of vaccine and ancillary items to end-user points as planned in the NDVPs.....	28
V. Public information and communications.....	29
Public perceptions and concerns about pandemic A(H1N1) 2009 vaccine	29
Communication strategies for priority groups.....	30
VI. Post-marketing surveillance	30
VII. Lessons learned.....	31
Communications	31
Vaccine packaging, availability, and transport issues.....	31
Planning and supervision	31
CONCLUSIONS.....	32
REFERENCES.....	33
ANNEXES	34
Annex I: List of countries that participated in the 2010 WHO A(H1N1) Survey	34

Annex II: Percentage of vaccine utilization and coverage in countries eligible for WHO-deployed vaccine, by region	35
Annex III: Percentage of vaccine utilization and coverage in non WHO-eligible countries, by region	38

Abbreviations and acronyms

AEFI	adverse effects following immunization
AFR	WHO African Region
AFRO	WHO Regional Office for Africa
AMR	WHO Region of the Americas
AMRO/PAHO	WHO Regional Office for the Americas/Pan American Health Organization
EMR	WHO Eastern Mediterranean Region
EMRO	WHO Regional Office for the Eastern Mediterranean
EUR	WHO European Region
EURO	WHO Regional Office for Europe
GAP	global pandemic influenza action plan to increase vaccine supply
MS	WHO Member States
NDVP	national deployment and vaccination plan
SAGE	Strategic Advisory Group of Experts on Immunization
SEAR	WHO South-East Asia Region
SEARO	WHO Regional Office for South-East Asia
UNICEF	United Nations Children's Fund
VENICE	Vaccine European New Integrated Collaboration Effort
WPR	WHO Western Pacific Region
WPRO	WHO Regional Office for the Western Pacific

Acknowledgements

The World Health Organization (WHO) would like to acknowledge and thank the following Member States for their participation in the 2010 global survey.

Africa Region: Central African Republic, Congo, Gambia, Guinea, Lesotho, Liberia, Mauritania, Namibia, Niger, Sao Tomé et Príncipe, Senegal, Seychelles, Sierra Leon, and Togo.

Americas Region: Argentina, Barbados, Belize, Bolivia, Brazil, the Cayman Islands, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Honduras, Jamaica, Nicaragua, Panama, Paraguay, Saint Lucia, Suriname, Trinidad and Tobago, and Uruguay.

Eastern Mediterranean Region: Afghanistan, Bahrain, Egypt, Iran, Jordan, Lebanon, Oman, and the Syrian Arab Republic.

European Region: Armenia, Azerbaijan, Georgia, Kosovo, Kyrgyzstan, the Republic of Moldova, and Tajikistan.

South East Asia Region: Bangladesh, Indonesia, Maldives, Nepal, Sri Lanka, Thailand, and Timor-Leste.

Western Pacific Region: Australia, Cambodia, China, Cook Islands, Fiji, Kiribati, Lao People's Democratic Republic, Malaysia, Marshall Islands, Mongolia, Nauru, New Caledonia, New Zealand, Niue, Palau, Papua New Guinea, Philippines, the Republic of Korea, Samoa, Singapore, Solomon Islands, Tokelau, Tonga, Tuvalu, and Vanuata.

The Organization also wishes to thank the many donors, governments, technical agencies, and private sector organizations for their support of the WHO pandemic A(H1N1) 2009 vaccine deployment initiative.

WHO would also like to thank its staff from headquarters and the regional offices for their contribution in developing the tools, facilitating the implementation of the surveys, and providing input to the analyses. From headquarters: Marie-Paule Kieny, John S. Tam, Claudia Vivas Torrealba, Kanokporn Coninx, and Reka Balla. From the African Regional Office: Richard Alombah, Afework Assefa, Patrick Byaruhang, Amos Chweya, Seka Leone, Jean Negantchou, Abdulquadir Oni, Richard Mihigo, and Adam Zenaw. From the Americas Regional Office: Alba Maria Roperio, Thais Dos Santos, and Hannah Kurtis. From the Eastern Mediterranean Regional Office: Ezzeddine Mohsni and Dalia Samhoury. From the European regional Office: Pernille Jorgensen, Rebecca Martin, and Annemarie Wasley. From the South East Asia Regional Office: Jayantha Liyange. From the Western Pacific Regional Office: Md. Shafiqul Hossain.

EXECUTIVE SUMMARY

Globally, influenza is a significant public health issue and vaccination is one of the most important medical interventions that can be used for reducing morbidity and mortality. On 11 June 2009, the World Health Organization (WHO) raised its pandemic alert to the highest level in view of the rapid global spread of the A(H1N1)pdm 2009 virus. With support from and in collaboration with Member States and partners, WHO strengthened its pandemic preparedness and response activities. Vaccination is crucial to pandemic mitigation efforts and the availability of pandemic vaccine, particularly in low and middle income countries, proved challenging. Many Member States and partners pledged support, including vaccines and additional resources for countries in need of the pandemic A(H1N1) 2009 vaccine. WHO set out a two-phase approach for supplying vaccines sufficient for immunizing 10% of the population in eligible countries based on the timing required to fulfill the pledges from Member States and partners.

The aim of this study is to assess the degree to which national pandemic vaccine deployment and vaccination plans (NDVPs) were implemented and to consolidate and distil lessons learned from the six WHO regions in an effort to improve future planning and to identify information that may have general applications.

In total, 84 out of 194 Member States (43%), including 51 out of 77 Member States (66%) who were eligible for and received WHO vaccine, participated in the survey (Table 1). In addition to the survey entries, further verifiable data were obtained from NPVD activity reports from countries.

The major findings of the survey include:

- Out of a total of 1.18 billion doses of pandemic A(H1N1) 2009 vaccine received by 163 countries, WHO provided 78.06 million doses to 77 countries through the WHO Pandemic Influenza A(H1N1) Vaccine Deployment Initiative. Demand for vaccines varied with the changing epidemiology of the pandemic as the virus spread across the globe and, as the level of concern about the virus diminished, demand for vaccine was reduced. The cost of vaccination was also a constraining factor for countries and limited the quantity of and demand for vaccine. This factor became more important as the level of concern for the pandemic decreased.
- The main suppliers of pandemic A(H1N1) 2009 vaccines included GlaxoSmithKline, Novartis, and Sanofi Pasteur, supplemented by Butantan, Green Cross, and MedImmune.
- Of the countries participating in this survey, 55% indicated that they implemented all activities as spelled out in their NDVPs. In most regions, countries reported high percentages of supervisory visits executed, with supervisors providing final reports on vaccine deployment and vaccination activities in countries where vaccination campaigns were completed.
- Overall, 56% of countries across all of the regions reported having sufficient supply chain and logistics capacity, with the exception of communications hardware, to deploy and administer pandemic A(H1N1) 2009 vaccines. Likewise, 68% of responding countries reported that vaccine and ancillary items were delivered to 80% of end users within seven days of receiving their material.
- With regard to public information and communications, the public's main concerns were vaccine safety as reported by 86% of countries, the need for the vaccine (75%), vaccine

efficacy (50%), and vaccine benefits (25%). Communication strategies were developed for various priority groups including health-care workers, pregnant women, persons with chronic medical conditions, and essential personnel, along with children and persons over 65 years of age.

- The majority of countries (85%) reported having a functioning adverse effects following immunization (AEFI) surveillance system during vaccination campaigns. In countries with no such system, reporting sheets and standard operating procedures (SOP) were developed for AEFI associated with pandemic A(H1N1) 2009 vaccination.

Lessons learned most frequently concerned communications. Many countries recommended improving public communications campaigns, enhancing pre-campaign education, providing better focus on priority groups, and effectively and vigorously addressing all anti-vaccination rumors. Vaccine availability needs to be timely and refrigeration infrastructure needs to be enhanced and better maintained. Planning and supervision need to be supported with better information and also logistics and management need to be based on a multi-sectoral approach, with campaign coordination beginning at least several weeks before activities are set in motion.

Pandemic preparedness is an ongoing concern, and this study provides information about the degree to which NDVPs were implemented in the deployment and utilization of pandemic A(H1N1) 2009 vaccines. It has also identified strengths and weaknesses in implementing the constitutive activities of these plans. This information, along with the lessons learned and guidance developed, will be useful for future pandemic planning and will also direct attention to those regions and countries where help is most needed.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28189

